GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » MARX Biotech Co Ltd (ROCO:7731) » Definitions » EBIT

MARX Biotech Co (ROCO:7731) EBIT : NT$-68.6 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is MARX Biotech Co EBIT?

MARX Biotech Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$-50.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-68.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MARX Biotech Co's annualized ROC % for the quarter that ended in Jun. 2024 was -39.39%. MARX Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -106.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. MARX Biotech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -1.87%.

MARX Biotech Co EBIT Historical Data

The historical data trend for MARX Biotech Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MARX Biotech Co EBIT Chart

MARX Biotech Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBIT
- 17.69 5.02 -15.12

MARX Biotech Co Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial -3.67 8.69 2.57 -17.68 -50.89

Competitive Comparison of MARX Biotech Co's EBIT

For the Pharmaceutical Retailers subindustry, MARX Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MARX Biotech Co's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MARX Biotech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MARX Biotech Co's EV-to-EBIT falls into.


MARX Biotech Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-68.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MARX Biotech Co  (ROCO:7731) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MARX Biotech Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-83.872 * ( 1 - -1.73% )/( (168.371 + 264.821)/ 2 )
=-85.3229856/216.596
=-39.39 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=394.847 - 73.649 - ( 152.827 - max(0, 101.036 - 343.043+152.827))
=168.371

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=413.459 - 50.681 - ( 97.957 - max(0, 164.694 - 350.403+97.957))
=264.821

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

MARX Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-101.782/( ( (4.257 + max(87.749, 0)) + (12.316 + max(87.685, 0)) )/ 2 )
=-101.782/( ( 92.006 + 100.001 )/ 2 )
=-101.782/96.0035
=-106.02 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(98.166 + 70.001 + 19.356) - (73.649 + 0 + 26.125)
=87.749

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(126.329 + 92 + 28.606) - (50.681 + 0 + 108.569)
=87.685

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

MARX Biotech Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-68.573/3660.151
=-1.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MARX Biotech Co EBIT Related Terms

Thank you for viewing the detailed overview of MARX Biotech Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

MARX Biotech Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » MARX Biotech Co Ltd (ROCO:7731) » Definitions » EBIT
Comparable Companies
Traded in Other Exchanges
N/A
Address
5th Floor, No. 655, Bannan Road, Zhonghe district, New Taipei, TWN
Website
https://www.marxbiotech.com
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.

MARX Biotech Co Headlines

No Headlines